The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of metronomic chemotherapy (MC) with bevacizumab (B) in patients (Pts) with advanced (Adv) nonsquamous non-small cell lung cancer (NS-NSCLC).
Carrie Lee Marquette
No relevant relationships to disclose
Stefan C. Grant
No relevant relationships to disclose
Mollie DeShazo
No relevant relationships to disclose
Vishnu Reddy
No relevant relationships to disclose
Alan Cantor
No relevant relationships to disclose
Debi Miley
No relevant relationships to disclose
Mary Jerome
No relevant relationships to disclose
Francisco Robert
Research Funding - University of Alabama